Follow-up information on 36 of the 44 patients categorized as M0 revealed that only 23% of patients who showed low TWIST1 expression developed metastatic disease, whereas 58% of patients with high TWIST1 expression later developed metastatic disease (P = .037; Supplementary Figure S2) further highlighting the possible importance of TWIST1 expression as a prognostic biomarker in medulloblastoma patients. Here, TWIST1 is linked to medulloblastoma.